| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/2003 | US6552070 Protective action on liver function against exogenous and endogenous hepatotoxic agents |
| 04/22/2003 | US6552067 EP4 receptor selective agonists in the treatment of osteoporosis |
| 04/22/2003 | US6552066 Protein tyrosine kinase inhibitors for treating osteoarthritis |
| 04/22/2003 | US6552064 Side effect reduction |
| 04/22/2003 | US6552063 Veterinary medicine |
| 04/22/2003 | US6552062 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity |
| 04/22/2003 | US6552059 Pharmaceutical composition for and method of treating leukemia |
| 04/22/2003 | US6552058 Oxazolidinedione derivatives and their use |
| 04/22/2003 | US6552057 Serotonin 5-HT3 receptor partial activator |
| 04/22/2003 | US6552055 Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| 04/22/2003 | US6552053 Suppressing or enhancing attentive cognition in a mammal, and administering a compound that modulates carbonic anhydrase activity in the brain in an amount sufficient to suppress or enhance attentive cognition. |
| 04/22/2003 | US6552051 Useful as high energy oxidizing agents in explosive and propellant formulations, and drugs for vasodilation |
| 04/22/2003 | US6552050 Method for enhancing protective cellular responses to genotoxic stress in skin |
| 04/22/2003 | US6552049 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans |
| 04/22/2003 | US6552048 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals |
| 04/22/2003 | US6552047 H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use |
| 04/22/2003 | US6552046 Cisapride |
| 04/22/2003 | US6552045 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| 04/22/2003 | US6552044 Indane or dihydroindole derivatives |
| 04/22/2003 | US6552043 Benzimidazolinyl piperidines as CGRP ligands |
| 04/22/2003 | US6552042 Anticoagulants |
| 04/22/2003 | US6552041 Cyclized amide derivatives useful for treating or preventing neuronal damage associated with neurological disease |
| 04/22/2003 | US6552040 Use of nitroxides in wound healing and in the prevention of photodamage |
| 04/22/2003 | US6552038 Anticoagulant agents |
| 04/22/2003 | US6552036 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 04/22/2003 | US6552035 Composition for inducing smoking cessation comprising alkaloids from Radix ipecauanhae |
| 04/22/2003 | US6552031 Synergistic analgesic combination of oxycodone and rofecoxib |
| 04/22/2003 | US6552030 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine |
| 04/22/2003 | US6552029 For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis |
| 04/22/2003 | US6552028 Inhibiting the binding of eotaxin to chemokine-3 (ccr-3) receptor; antiasthmatics |
| 04/22/2003 | US6552027 4-((3-hydroxyphenyl)amino),6,7-dimethoxy-quinazoline for example; conjugates with epidermal growth factor |
| 04/22/2003 | US6552025 Diimino-piperazine derivatives for use as modulators of cell regulation |
| 04/22/2003 | US6552024 For administering agents in a dissolving film configuration; drug delivery |
| 04/22/2003 | US6552022 Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels |
| 04/22/2003 | US6552020 Compositions including antibiotics and methods for using same |
| 04/22/2003 | US6552019 Inhibitors of p38 |
| 04/22/2003 | US6552017 Substituted heterocycle fused gamma-carbolines |
| 04/22/2003 | US6552016 For inhibiting aberrant growth states resulting from hedgehog gain- of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule |
| 04/22/2003 | US6552015 Azabicycloalkane derivatives and therapeutic uses thereof |
| 04/22/2003 | US6552014 Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| 04/22/2003 | US6552012 Heteroaryl diazabicycloalkanes, their preparation and use |
| 04/22/2003 | US6552011 (Androst-5-en-17beta -yl)alkyl sulfoxides and sulfones and their use for control of fertility |
| 04/22/2003 | US6552010 Treatment of SLE with dehydroepiandrosterone |
| 04/22/2003 | US6552009 Compositions and methods of treating abnormal cell proliferation |
| 04/22/2003 | US6552008 Administering effective amount of a selected azo-pyrazole derivative for therapy of thrombocytopenia |
| 04/22/2003 | US6552002 Miticides, parasiticides; veterinary medicine |
| 04/22/2003 | US6552001 Administering heat treatment product of compound selected from uronic acid or a uronic acid derivative, a saccharide containing uronic acid and/or a uronic acid derivative; 4,5-dihydroxy-2-cyclopenten-1-one to organism |
| 04/22/2003 | US6552000 Anticonvulsant derivatives useful in treating autism |
| 04/22/2003 | US6551993 Administering partial glycine agonist to the glycine modulatory site of the NMDA receptor complex of mammals for therapy of cognitive dysfunction such as inattention |
| 04/22/2003 | US6551989 Preventing airway mucus production by administration of EGF-R antagonists |
| 04/22/2003 | US6551816 Enzymatic method for preparing synthesis intermediates |
| 04/22/2003 | US6551799 Nucleotide sequences coding polypeptide for use in diagnosis and treatment of pancreatic defects |
| 04/22/2003 | US6551627 Medicinal herbal compounds for the prevention and treatment of diabetes |
| 04/22/2003 | US6551626 Composition containing pyrrolizidine-alkaloid-free petasites |
| 04/22/2003 | US6551623 Immunomodulating compositions from bile |
| 04/22/2003 | US6551621 A protective coatings for improving drug stability over time; treatment of gastric and duodenal ulcers |
| 04/22/2003 | US6551620 Pellet formulation for the treatment of the intestinal tract |
| 04/22/2003 | US6551617 Taste masking coating composition |
| 04/22/2003 | US6551616 Reducing gastrointestinal adverse side effects and improving taste |
| 04/22/2003 | US6551615 Capsule containing dexibuprofen (ibuprofen) dissolved in a solubilizer, a potassium salt forming compound, surfactants, co-surfactants, and a viscosity imparter; bioavailability |
| 04/22/2003 | US6551613 Dosage form comprising therapeutic formulation |
| 04/22/2003 | US6551612 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 04/22/2003 | US6551611 Hormone replacement therapy method |
| 04/22/2003 | US6551607 Method for sequestration of skin irritants with substrate compositions |
| 04/22/2003 | US6551604 Skin care compositions |
| 04/22/2003 | US6551602 Conjugated linoleic acid (CLA) compound in cis9 trans11 and trans10 cis 12 isomer forms, and epigallocatechin gallate, genistein, green tea extract and/or soy extract; treating wrinkles and soothing sensitive |
| 04/22/2003 | US6551596 Fractions of Chlorella extract containing polysaccharide having immunomodulating properties |
| 04/22/2003 | US6551594 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method |
| 04/22/2003 | US6551590 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW |
| 04/22/2003 | US6551588 Administering at or around the solid tumor an expressible nucleic acid encoding interleukin-3, and providing a tumor antigen, then treating the tumor with radiotherapy |
| 04/22/2003 | US6551586 Merozoite surface antigen1 (MSA1); vaccinia virus expression vector which expresses a malaria MSA1 peptide in combination with a signal peptide and anchor peptide in a host animal |
| 04/22/2003 | US6551584 Topical antibiotic composition for treatment of eye infection |
| 04/22/2003 | US6551578 Stability, aerosols, drug delivery; therapy |
| 04/22/2003 | US6551577 Topical spray for burn treatment and anti-infection |
| 04/22/2003 | US6550955 Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface |
| 04/22/2003 | US6550482 Methods for non-permanent occlusion of a uterine artery |
| 04/22/2003 | US6550474 Microencapsulated fragrances and methods of coating microcapsules |
| 04/22/2003 | CA2408681A1 Process for the preparation of chondroitin sulfates from k4 polysaccharide and obtained products |
| 04/22/2003 | CA2308780C Novel derivatives of 2,3-methanoamino acids, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2003 | CA2304784C A transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof |
| 04/22/2003 | CA2292673C Pharmaceutical compositions containing eletriptan hemisulphate |
| 04/22/2003 | CA2287054C 1,3,8-triazaspiro¬4,5|decanone compounds as orl1-receptor agonists |
| 04/22/2003 | CA2281580C Quinoxalinediones |
| 04/22/2003 | CA2264960C External formulation containing loxoprofen |
| 04/22/2003 | CA2253869C Substituted oxobutyric acids as matrix metalloprotease inhibitors |
| 04/22/2003 | CA2239187C Inhibitors of farnesyl protein transferase |
| 04/22/2003 | CA2222713C Composition comprising d-threo-methylphenidate and another drug |
| 04/22/2003 | CA2152941C Cytopathic viruses for therapy and prophylaxis of neoplasia |
| 04/22/2003 | CA2117471C Benzisoxazole derivatives and pharmaceutical compositions containing them |
| 04/22/2003 | CA2068630C Use of protein c or activated protein c |
| 04/22/2003 | CA2061520C Delivery system for enhanced onset and increased potency |
| 04/19/2003 | CA2408797A1 Treatment of breast cancer |
| 04/19/2003 | CA2361882A1 Liquid for oral administration comprising paroxetine |
| 04/19/2003 | CA2361863A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 04/19/2003 | CA2361345A1 Topical solutions for the treatment of nasal symptoms in the common cold for newborn infants, children and adults |
| 04/17/2003 | WO2003031987A2 In vitro model for priocidal activity |
| 04/17/2003 | WO2003031643A2 Methods for regulating co-stimulatory molecule expression with reactive oxygen |
| 04/17/2003 | WO2003031606A2 Crystal structure of an aurora kinase catalytic domain, and use thereof |
| 04/17/2003 | WO2003031597A2 Methods of inhibiting osteoclast activity |
| 04/17/2003 | WO2003031587A2 Use of stat-6 inhibitors as therapeutic agents |